CELU · Celularity Inc · Executive Compensation
$1.68
+0.08 (+5.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated the Company's current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Sep 29, 2026
Market Cap
$43.81M
Shares
32.45M
Volume · Oct 5
279.66K
Avg daily vol (3M)
3.9M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Adrian Kilcoyne | M.D., M.P.H., M.B.A. Former Executive Vice President and Chief Medical Officer | $1,238,065 |
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $1,234,342 |
| John R. Haines | Executive Vice President and Chief Administrative Officer | $815,815 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $5,242,529 |
| John R. Haines | Executive Vice President and Chief Administrative Officer | $2,503,571 |
| David C. Beers | Chief Financial Officer | $1,705,032 |
| Adrian Kilcoyne | M.D., M.P.H., M.B.A. Former Executive Vice President and Chief Medical Officer | $267,583 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $21,819,756 |
| Andrew L. Pecora | M.D., F.A.C.P. President | $9,050,997 |
| John R. Haines | Senior Executive Vice President, General Manager and Chief Administrative Officer | $4,026,127 |
| David C. Beers | Chief Financial Officer | $1,474,899 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $2,681,654 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Diane Parks | the Board | Resigned | 2026-09-29 |
| Naveen Jain | member of the Board | Appointed | 2026-09-29 |
| Philip A. Barach | Collateral Agent | Appointed | 2026-09-28 |
| Philip A. Barach | director | Appointed | 2026-09-28 |
| Geoffrey Ling, M.D., Ph.D. | the Board | Resigned | 2026-09-28 |
| Rick Gonzalez | Chief Commercial Officer | Terminated | 2026-08-07 |
| Vincent LeVien | member of the Company's Board of Directors | Resigned | 2026-06-30 |
| Steven N. Gordon, Esq. | member of the Board | Appointed | 2026-06-25 |
| K. Harold Fletcher, Esq. | Chief Legal and Strategy Officer and Corporate Secretary | Appointed | 2026-06-25 |
| Steven N. Gordon, Esq. | Chief Operating and Administrative Officer | Appointed | 2026-06-25 |
| Rick Gonzalez | Chief Commercial Officer | Appointed | 2026-06-03 |
| Stephen A. Brigido | President, Degenerative Diseases | Resigned | 2026-04-21 |
| John R. Haines | Senior Vice President, Global Manager and Chief Administrative Officer | Terminated | 2026-04-21 |
| John Sprague | Acting Chief Financial Officer | Appointed | 2026-03-05 |
| Joseph DosSantos | interim CFO | Appointed | 2025-06-10 |
| David Beers | Chief Financial Officer | Terminated | 2025-06-10 |
| Vincent LeVien | Class II director | Appointed | 2025-06-06 |
| Dean Kehler | member of the Board of Directors | Resigned | 2025-05-16 |
| Adrian Kilcoyne | Executive Vice President and Chief Medical Officer | Resigned | 2024-09-13 |
| Richard J. Berman | Class II director | Appointed | 2024-08-28 |
| Marc Mazur | Class III member of the Board of Directors | Resigned | 2024-08-05 |
| Robin L. Smith, MD | member of the board of directors | Resigned | 2023-12-29 |
| Lim Kok Thay | member of the board of directors | Resigned | 2023-09-19 |
| Geoffrey Shiu Fei Ling | Class I director | Appointed | 2023-09-07 |
| Andrew C. von Eschenbach | Class I member of the board of directors | Resigned | 2023-09-07 |